Astria Therapeutics (NASDAQ:ATXS) PT Lowered to $16.00

Astria Therapeutics (NASDAQ:ATXS) had its target price dropped by analysts at HC Wainwright from $18.00 to $16.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 77.78% from the company’s previous close.

Several other analysts have also weighed in on ATXS. Jefferies Financial Group increased their price target on Astria Therapeutics from $22.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 25th. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Astria Therapeutics in a report on Tuesday, March 26th.

Astria Therapeutics Trading Down 6.6 %

Shares of ATXS stock opened at $9.00 on Tuesday. The company’s fifty day moving average price is $13.31 and its 200-day moving average price is $9.27. The stock has a market cap of $494.13 million, a PE ratio of -3.85 and a beta of 0.69. Astria Therapeutics has a 12 month low of $4.26 and a 12 month high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, sell-side analysts forecast that Astria Therapeutics will post -1.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Astria Therapeutics

In other Astria Therapeutics news, Director Perceptive Advisors Llc acquired 2,481,350 shares of the stock in a transaction dated Thursday, February 1st. The stock was acquired at an average cost of $12.09 per share, with a total value of $29,999,521.50. Following the transaction, the director now owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Perceptive Advisors Llc bought 2,481,350 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was purchased at an average cost of $12.09 per share, with a total value of $29,999,521.50. Following the transaction, the director now directly owns 4,873,721 shares in the company, valued at $58,923,286.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Christopher Morabito sold 9,200 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $11.15, for a total value of $102,580.00. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

Institutional Trading of Astria Therapeutics

Institutional investors have recently modified their holdings of the business. AJOVista LLC purchased a new stake in shares of Astria Therapeutics in the fourth quarter valued at approximately $51,000. Jump Financial LLC purchased a new stake in Astria Therapeutics during the third quarter worth $111,000. Panagora Asset Management Inc. purchased a new stake in shares of Astria Therapeutics in the fourth quarter valued at $119,000. Trexquant Investment LP purchased a new stake in shares of Astria Therapeutics in the fourth quarter valued at $409,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Astria Therapeutics in the fourth quarter valued at $1,469,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.